

**EVALUATION OF EDUCATION AND  
ECONOMIC BARRIERS IN IMPLEMENTING  
ESSENTIAL MEDICINES CONCEPT IN  
MALAYSIA**

**HIND MAHJOWB ABDALLAH AHMED**

**UNIVERSITI SAINS MALAYSIA**

**2009**

**EVALUATION OF EDUCATION AND  
ECONOMIC BARRIERS IN IMPLEMENTING  
ESSENTIAL MEDICINES CONCEPT IN  
MALAYSIA**

**by**

**HIND MAHJOWB ABDALLAH AHMED**

**Thesis submitted in fulfillment of the requirements for the degree of  
Master of Science**

**June 2009**

## DEDICATION

*I dedicate this work to my husband Bakri Elamein  
Yousif, my mother Amal Elimam, my father, my sons  
Mohammad and Omer, and my brothers Osman and  
Omer*

*Thank you for the love and sacrifices*

## ACKNOWLEDGEMENTS

I would like to express my heartfelt gratitude and appreciation to Allah who bestowed on me the power and patience to complete this study. I also would like to express sincere gratitude and deep appreciation to my supervisor, Professor Mohamed Izham Mohamed Ibrahim, PhD for his scientific guidance, invaluable advices, unfailing support and encouragement throughout my study. Without his assistance, this work probably would not have been completed. I really appreciate his intellectual capabilities and constructive criticisms. I am also grateful to my field-supervisor Dr. Zaheer Ud-Din Babar for his support, invaluable advices and his guidance before he left for New Zealand.

My sincere appreciations also go to Dr. Mohamed Azmi Ahmad Hassali, Dr. Azrul Akmal Shafie and Dr. Mahmoud Sa'di Al-haddad for their guidance and invaluable advices during my presentations through out my study and through the social pharmacy yahoo group discussion. Many thanks and appreciations go to all friends and colleagues in Social and Administrative Pharmacy Discipline for their help and support. Also, I would like to thank Associate Professor Dr. Syed Azhar Syed Sulaiman (Dean of School of Pharmaceutical Science) and the Dean of the Institute of Postgraduate Studies for providing me opportunity to finish my study in the field of Social and Administrative Pharmacy.

Special thanks to Dr. Norlela Maarup for her technical support. I will never forget the help, kindness and support of all Sudanese in Penang, especially Sohair Elteib, Hisham Elhag and Hamid Mahmoud.

Finally, I am very grateful to my husband Bakri Elamein Yousif for his moral and financial support to pursue this study.

## TABLE OF CONTENTS

<b>Title</b>	<b>Page</b>
<b>DEDICATION</b>	ii
<b>ACKNOWLEDGEMENTS</b>	iii
<b>TABLE OF CONTENTS</b>	iv
<b>LIST OF TABLES</b>	xiv
<b>LIST OF FIGURES</b>	xviii
<b>LIST OF APPENDICES</b>	xxii
<b>ABBREVIATION</b>	xxiii
<b>ABSTRAK</b>	xxiv
<b>ABSTRACT</b>	xxvi
<b>CHAPTER ONE: GENERAL INTRODUCTION</b>	1
<b>1.1 BACKGROUND</b>	1
1.1.1 Definition and general principles of essential medicines	1
1.1.2 Essential medicines concept	2
1.1.2 (a) Practical implications of essential medicines concept	3
1.1.2 (b) Challenges facing essential medicines concept	4
1.1.2 (c) Barriers to implementing essential medicines concept	4
i. Medicine availability	4
ii. Economic barriers	5
iii. Education barriers	6
iv. Patent regulations	8

<b>Title</b>	<b>Page</b>
v. Technical barriers	10
vi. Political barriers	10
1.1.3 Promoting essential medicines concept	11
1.1.4 Advantages of essential medicines list	13
1.1.5 Selection of essential medicines	14
1.1.5 (a) Selection criteria	15
1.1.5 (b) Committee for selection of essential medicines	17
1.1.6 Updating essential medicines list	17
1.1.7 Essential medicines for special cases	17
1.1.7 (a) Essential medicines for children	17
1.1.7 (b) Essential medicines for rare diseases	18
1.1.8 Implementation of essential medicines list in Malaysia	18
<b>1.2 Problem statement</b>	22
1.2.1 Health professional awareness on essential medicines in Western Pacific Region	22
1.2.2 Medicines affordability in Malaysia	22
<b>1.3 Rationale of the study</b>	24
<b>1.4 Research objectives</b>	25
1.4.1 General aim	25
1.4.2 Specific objectives	25
1.4.2 (a) Objectives of survey on prescribers and pharmacists	25
1.4.2 (b) Objectives of survey on medical and pharmacy students	25
1.4.2 (c) Objectives of medicines affordability evaluation	26

<b>Title</b>	<b>Page</b>
<b>1.5 Literature review</b>	27
1.5.1 Awareness on essential medicines concept	27
1.5.2 Education activities regarding essential medicines	28
1.5.3 Essential medicines affordability	28
<b>1.6 Significance of the study</b>	33
 <b>CHAPTER TWO: PRESCRIBERS AND PHARMACISTS</b>	34
<b>AWARENESS ON ESSENTIAL MEDICINES CONCEPT</b>	
<b>2.1 Introduction</b>	34
<b>2.2 Objectives</b>	36
<b>2.3 Methodology</b>	37
2.3.1 Study design	37
2.3.2 Study population	37
2.3.3 Sample size and sampling procedure	38
2.3.4 Instrument and questionnaire design	41
2.3.5 Data collection procedure and time	44
2.3.6 Data analysis	45
<b>2.4 Results</b>	46
2.4.1 Survey on prescribers' knowledge	46
2.4.1 (a) General description of respondents	46
i. Survey response rate	46
ii. General characteristics of respondents	46
iii. Distribution of respondents	49
2.4.1 (b) Knowledge about Malaysian national EML	50

<b>Title</b>	<b>Page</b>
2.4.1 (c) Knowledge about essential medicines concept	51
2.4.1 (d) Prescribers' attitude	53
2.4.1 (e) Prescribers' practice	55
2.4.1 (f) Respondents' score	56
2.4.1 (g) Variation between demographic data and respondents' score	57
i. Gender	57
ii. Ethnic group	58
iii. Prescribers' practice category	60
iv. Age	61
v. Years of experience	62
2.4.2 Survey on pharmacists' knowledge	63
2.4.2 (a) General description of respondents	63
i. Survey response rate	63
ii. General characteristics of respondents	63
iii. Distribution of respondents	66
2.4.2 (b) Knowledge about Malaysian national EML	66
2.4.2 (c) Knowledge about essential medicines concept	67
2.4.2 (d) Pharmacists' attitude	69
2.4.2 (e) Pharmacists' practice	71
2.4.2 (f) Pharmacists' score	72
2.4.2 (g) Variation between demographic data and respondents' score	73
i. Gender	73
ii. Ethnic group	74



<b>Title</b>	<b>Page</b>
iii. Higher degree	76
iv. Age	77
v. Years of experience	78
2.4.3 Comparison between prescribers' and pharmacists' scores	80
2.4.3 (a) Knowledge portion	80
2.4.3 (b) Attitude portion	81
2.4.3 (c) Practice portion	83
<b>2.5 Discussion</b>	86
2.5.1 Analysis of prescribers' and pharmacists' awareness	86
2.5.1 (a) Demographic analysis	86
2.5.1 (b) Knowledge about Malaysian national EML	87
2.5.1 (c) Respondents' score	88
2.5.1 (d) Variation between demographic data and respondents' scores	93
2.5.3 Comparative analysis between prescribers' and pharmacists' scores	95
<b>2.6 Conclusion</b>	96
 <b>CHAPTER THREE: ASSESSMENT ON MEDICAL AND PHARMACY STUDENTS AWARENESS AND UNIVERSITY CURRICULUM ON ESSENTIAL MEDICINES CONCEPT</b>	97
<b>3.1 Introduction</b>	97
<b>3.2 Objectives</b>	98
<b>3.3 Methodology</b>	99

<b>Title</b>	<b>Page</b>
3.3.1 Assessment on students	99
3.3.1 (a) Study design	99
3.3.1 (b) Study population	99
3.3.1 (c) Sample size and sampling procedure	99
3.3.1 (d) Instrument and questionnaire design	101
3.3.1 (e) Data collection procedure and time	103
3.3.1 (f) Data analysis	104
3.3.2 University curriculum assessment	104
3.3.2 (a) Study design	104
3.3.2 (b) Study population	105
3.3.2 (c) Instrument and questionnaire design	105
3.3.2 (d) Sample size and sampling procedure	106
3.3.2 (e) Data collection procedure and time	106
<b>3.4 Results</b>	107
3.4.1 Assessment on students	107
3.4.1 (a) General description of respondents	107
i. Survey response rate	107
ii. General characteristics of respondents	107
iii. Distribution of respondents	108
3.4.1 (b) Knowledge about Malaysian national EML	110
3.4.1 (c) Knowledge about essential medicines concept	111
i. Overall response to knowledge items	111
ii. Differences between medical and pharmacy students responses in knowledge items	113

<b>Title</b>	<b>Page</b>
2.4.1 (d) Students' attitude	115
i. Overall response to attitude items	115
ii. Differences between medical and pharmacy students responses in attitude items	116
2.4.1 (f) Respondents' score	117
2.4.1 (e) Variation between demographic data and respondents score	118
i. Gender	118
ii. Ethnic group	119
iii. Schools	120
iv. Universities	121
v. Respondents' institutes	123
3.4.2 University curriculum assessment	125
3.4.2 (a) Respondents and response rate	125
3.4.2 (b) Educational activities by schools	125
i. Type of involvement of EMC in the curriculum	125
ii. Number of hours spent in educating students about essential medicines concept	127
iii. Names of courses	127
3.4.2 (c) Types of educational techniques	128
3.4.2 (d) Main objectives of educating essential medicines concept	129
3.4.2 (e) Including essential medicines concept into students examination	129
3.4.2 (f) Evaluation of educational program	129
3.4.2 (g) Opinions on success of educational program	130

<b>Title</b>	<b>Page</b>
3.4.2 (h) Barrier to success	130
3.4.2 (i) Types of course materials developed	131
<b>3.5 Discussion</b>	132
3.5.1 Analysis of students' awareness	132
2.5.1 (a) Demographic analysis	132
2.5.1 (b) Knowledge about Malaysian national EML	132
2.5.1 (c) Respondents' score	133
2.5.1 (d) Variation between demographic data and scores	134
3.5.2 University curriculum assessment	135
<b>3.6 Conclusion</b>	137
 <b>CHAPTER FOUR: AFFORDABILITY OF ESSENTIAL MEDICINES USED IN TREATING CHRONIC DISEASES</b>	 138
<b>4.1 Introduction</b>	138
<b>4.2 Objectives</b>	139
<b>4.3 Methodology</b>	140
4.3.1 Study design	140
4.3.2 Study population	140
4.3.2 (a) Inclusion criteria	141
4.3.2 (b) Exclusion criteria	141
4.3.3 Sample size and sampling procedure	141
4.3.4 Data collection instrument	142
4.3.5 Study location	143
4.3.6 Data analysis	143

<b>Title</b>	<b>Page</b>
<b>4.4 Results</b>	<b>144</b>
4.4.1 Medicines prices	144
4.4.2 Affordability	146
4.4.2 (a) Affordability of medicines used in treating hypertensive patients	146
4.4.2 (b) Affordability of medicines used in treating diabetes mellitus type II patients	148
i. Prescriptions containing one medicine	148
ii. Prescriptions containing two medicines	150
4.4.2 (c) Affordability of medicines used in treating asthmatic patients	154
i. Prescriptions containing one medicine	154
A. Tablet dosage form	154
B. Inhaler dosage form	156
ii. Prescriptions containing two medicines	157
4.4.2 (d) Affordability of medicines using multiple cases conditions	162
<b>4.5 Discussion</b>	<b>166</b>
4.5.1 Hypertension treatments affordability	166
4.5.2 Diabetes mellitus type II treatments affordability	168
4.5.2 (a) Prescriptions containing one medicine	168
4.5.2 (b) Prescriptions containing two medicines	170
4.5.3 Asthma treatments affordability	170
4.5.3 (a) Prescriptions containing one medicine	170
i. Tablet dosage form	170
ii. Inhaler dosage form	171

<b>Title</b>	<b>Page</b>
4.5.3 (b) Prescriptions containing two medicines	171
4.5.4 Affordability of multiple cases medicines	172
<b>4.6 Conclusion</b>	173
 <b>CHAPTER FIVE: OVERALL CONCLUSION</b>	174
5.1 Conclusion	174
5.2 Recommendation	175
5.2.1 Pharmaceutical policy	175
5.2.2 Pharmacy practice	176
5.2.3 Future research	176
5.3 Limitations of the study	177
<b>BIBLIOGRAPHY</b>	178
<b>APPENDICES</b>	194
<b>LIST OF PUBLICATIONS</b>	239

## LIST OF TABLES

<b>Table No.</b>	<b>Title</b>	<b>Page</b>
Table 1.1	Chronology of major events before implementing the national EML in Malaysia	19
Table 1.2	Medicines prices in different sectors comparing with international reference price	23
Table 2.1	Hospitals' and clinics sampling	40
Table 2.2	Questions included in a survey of prescribers	43
Table 2.3	Questions included in a survey of pharmacists	44
Table 2.4	Prescribers' knowledge on EMC	51
Table 2.5	Prescribers' responses to attitude items	53
Table 2.6	Prescribers' responses to practice items	55
Table 2.7	Differences between prescribers' knowledge, attitude or practice on EMC based on gender	57
Table 2.8	The median score of prescribers' attitude on EMC based on gender	57
Table 2.9	Differences between prescribers' knowledge, attitude or practice on EMC based on ethnic group	58
Table 2.10	The median score of prescribers' attitude on EMC based on ethnic group	59
Table 2.11	Differences between prescribers' knowledge, attitude or practice on EMC based on prescribers' practice category	60
Table 2.12	The median score of prescribers' attitude on EMC based on practice category	61
Table 2.13	Prescribers' knowledge, attitude and practice on EMC correlated with age	61
Table 2.14	Prescribers' knowledge, attitude and practice on EMC correlated with years of experience	62
Table 2.15	Pharmacists' knowledge on EMC	67

Table 2.16	Pharmacists' responses to attitude items	69
<b>Table No.</b>	<b>Title</b>	<b>Page</b>
Table 2.17	Pharmacists' responses to practice items	71
Table 2.18	Differences between pharmacists' knowledge, attitude, practice on EMC based on gender	73
Table 2.19	Differences between pharmacists' knowledge, attitude, practice on EMC based on ethnic group	74
Table 2.20	The median score of pharmacists' attitude on EMC based on ethnic group	74
Table 2.21	The median score of pharmacists' practice on EMC based on ethnic group	75
Table 2.22	Differences between pharmacists' knowledge, attitude and practice on EMC based on higher degrees	76
Table 2.23	Pharmacists' knowledge, attitude and practice on EMC correlated with age	77
Table 2.24	Pharmacists' knowledge, attitude and practice on EMC correlated with years of experience	78
Table 2.25	A comparison between prescribers' and pharmacists' knowledge on EMC	80
Table 2.26	A comparison between prescribers' and pharmacists' positive attitudes on EMC	82
Table 2.27	Differences between health professionals' knowledge, attitude, practice on EMC based on position	84
Table 2.28	The median scores of attitude on EMC based on position	84
Table 2.29	The median scores of practice on EMC based on position	85
Table 3.1	Questions included in a survey on students	103
Table 3.2	Students' knowledge on EMC	111
Table 3.3	Comparison between medical and pharmacy student's knowledge on EMC	114
Table 3.4	Students' responses to attitude items	115



Table 3.5	Comparison between medical and pharmacy student's attitudes on EMC	116
<b>Table No.</b>	<b>Title</b>	<b>Page</b>
Table 3.6	Differences between students' knowledge and attitude on EMC based on gender	118
Table 3.7	The median score of students' knowledge on EMC based on gender	118
Table 3.8	Differences between students' knowledge and attitude on EMC based on ethnic groups	119
Table 3.9	Differences between students' knowledge, attitude, practice on EMC based on different schools	120
Table 3.10	The median score of students' knowledge on EMC based on schools	120
Table 3.11	Differences between students' knowledge and attitude on EMC based on different universities	121
Table 3.12	The median score of students' knowledge on EMC based on different universities	122
Table 3.13	The median score of students' knowledge on EMC based on respondents' institutions	123
Table 3.14	The median score of students' attitudes on EMC based on respondents' institutions	124
Table 3.15	Respondents to universities curricula survey	125
Table 3.16	Number of education activities within schools	125
Table 3.17	Types of education activities within school	126
Table 3.18	Courses names	127
Table 3.19	Types of educational techniques	128
Table 3.20	Objectives of educating EMC	129
Table 3.21	Education program' barriers of success	130
Table 3.22	Types of course materials developed to teach EMC	131
Table 4.1	Median prices per unit dose for medicines used in treatment of diabetes, hypertension and asthma	144

Table 4.2	Median cost for all essential medicines mentioned in hypertension' prescription	146
<b>Table No.</b>	<b>Title</b>	<b>Page</b>
Table 4.3	Median cost for medicines mentioned in prescription used in treatment of DM type II	149
Table 4.4	Median prescriptions costs required to pay for one month treatments of DM type II using Glibenclamide 5mg and Metformin 0.5 g tablets	150
Table 4.5	Median prescriptions costs required to pay for one month treatments of DM type II using Metformin 0.5 g and Gliclazide 80 mg tablets	152
Table 4.6	Median prescriptions costs required to pay for one month treatments of DM type II using Metformin 0.5 g and Gliclazide 80 mg tablets two tablets of each per day	153
Table 4.7	Prescriptions contents, median prescriptions costs required to pay for one month treatments of asthma using one drug in an oral dosage form	155
Table 4.8	Median prescriptions costs required to pay for one month treatments of asthma using one drug in a inhaler dosage form	156
Table 4.9	Median cost required to pay one for one month treatment of asthma using salbutamol 4 mg and theophylline 200 mg tablets	157
Table 4.10	Median prescriptions costs required to pay for one month treatments of asthma using ketotifen 1mg and salbutamol 2 mg tablets	158
Table 4.11	Median prescriptions costs required to pay for one month treatments of asthma using ketotifen 1mg and salbutamol 4 mg tablets	160
Table 4.12	Median prescriptions costs required to pay for one month treatments of asthma using terbutaline 1mg and salbutamol 4 mg tablets	161
Table 4.13	Median prescriptions costs of multiple case treatment using metformin 0.5 g, gliclazide 80 mg and atenolol 50 mg tablets	162
Table 4.14	Median prescriptions costs required to pay for one month treatment of multiple case conditions using metformin	164

0.5 g, gliclazide 80 mg and atenolol 50 mg tablets

## LIST OF FIGURES

<b>Figure No.</b>	<b>Title</b>	<b>Page</b>
Figure 2.1	Flow chart showing sampling procedure	39
Figure 2.2	Prescribers' gender	47
Figure 2.3	Prescribers' ethnic groups	47
Figure 2.4	Prescribers' practice category	48
Figure 2.5	Prescribers' age in years	48
Figure 2.6	Prescribers' years of experience	49
Figure 2.7	Prescribers' distribution between states	50
Figure 2.8	Prescribers' sources of knowledge about Malaysian national EML	51
Figure 2.9	Prescribers' rates of correct answers for knowledge items about EMC	52
Figure 2.10	Prescribers' source of information about EMC	53
Figure 2.11	Prescribers' responses items on attitude	55
Figure 2.12	Prescribers' responses items on practice	56
Figure 2.13	Correlation of prescribers' knowledge median score with years of experience	62
Figure 2.14	Pharmacists' gender	63
Figure 2.15	Pharmacists' ethnic groups	64
Figure 2.16	Pharmacists' higher degree	64
Figure 2.17	Pharmacists' age in years	65
Figure 2.18	Pharmacists' years of experience	65
Figure 2.19	Pharmacists' distribution among state	66
Figure 2.20	Pharmacists' sources of knowledge about Malaysian	67

	national EML	
Figure 2.21	Pharmacists' rates of correct answer for knowledge items about EMC	68
<b>Figure No.</b>	<b>Title</b>	<b>Page</b>
Figure 2.22	Information sources of pharmacists about EMC	69
Figure 2.23	Pharmacists' responses to items on attitude	71
Figure 2.24	Pharmacists' responses to items on practice	72
Figure 2.25	Correlation of pharmacists' knowledge median score with age	77
Figure 2.26	Correlation of pharmacists' attitude median score with age	78
Figure 2.27	Correlation of pharmacists' knowledge median score with years of experience	79
Figure 2.28	Correlation of pharmacists' practice median score with years of experience	79
Figure 2.29	Comparison between prescribers and pharmacists percentages of correct answers for each knowledge items	81
Figure 2.30	Comparison between prescribers and pharmacists percentages of agreement in attitude items	82
Figure 2.31	Comparison between prescribers and pharmacists percentages of total score for each practice items	83
Figure 2.32	Comparison between prescribers and pharmacists percentages of total score for knowledge, attitude and practice	83
Figure 3.1	Flow chart showing sampling procedure	100
Figure 3.2	Students' gender	107
Figure 3.3	Students' ethnic groups	108
Figure 3.4	Number of respondents per each university	108
Figure 3.5	Students' schools	109
Figure 3.6	Students' frequency in each institute	109
Figure 3.7	Students' sources of information about Malaysian	110

national EML

Figure 3.8	Rates of correctness for knowledge items about EMC	112
<b>Figure No.</b>	<b>Title</b>	<b>Page</b>
Figure 3.9	Information source of students about EMC	113
Figure 3.10	Comparison between medical and pharmacy students' correct answers for each knowledge items	114
Figure 3.11	Students' rates of response to attitude items	115
Figure 3.12	Comparison between medical and pharmacy students' percentages of agreement to attitude items	116
Figure 4.1	Methodology flow chart	142
Figure 4.2	Number of days' salary required to pay for one month treatments of hypertension	148
Figure 4.3	Number of days' salary required to pay for one month treatments of DM type II using one drug	150
Figure 4.4	Number of days' salary required to pay for one month treatments of DM type II using glibenclamide 5 mg and metformin 0.5 g tablets	151
Figure 4.5	Number of days' salary required to pay for one month treatments of DM type II using metformin 0.5 g and gliclazide 80 mg tablets	153
Figure 4.6	Number of days' salary required to pay for one month treatments of DM type II using metformin 0.5 g and gliclazide 80 mg tablets two tablets of each per day	154
Figure 4.7	Number of days' salary required to pay for one month treatments of asthma using one drug in an oral dosage form	156
Figure 4.8	Number of days' salary required to pay for one month treatments of asthma using one drug in a inhaler dosage form	157
Figure 4.9	Number of days' salary required to pay for one month treatments of asthma using salbutamol 4 mg and theophylline 200 mg tablets	158
Figure 4.10	Number of days' salary required to pay for one month treatments of asthma using ketotifen 1 mg and	159

salbutamol 2 mg tablets

<b>Figure No.</b>	<b>Title</b>	<b>Page</b>
Figure 4.11	Number of days' salary required to pay for one month treatments of asthma using ketotifen 1mg and salbutamol 4 mg tablets	161
Figure 4.12	Number of days' salary required to pay for one month treatments of asthma using terbutaline 1mg and salbutamol 4 mg tablets	162
Figure 4.13	Number of days' salary required to pay for one month treatments of multiple case condition using metformin 0.5 g, gliclazide 80 mg and atenolol 50 mg tablets	163
Figure 4.14	Number of days' salary required to pay for one month treatment of multiple case condition using gliclazide 80 mg and atenolol 50 mg tablets	165

## **LIST OF APPENDICES**

Appendix A	List of Malaysian public clinics	194
Appendix B	List of Malaysian public hospitals	199
Appendix C	Practitioners' pilot survey	203
Appendix D	The survey questionnaire for prescribers	210
Appendix E	The survey questionnaire for pharmacists	214
Appendix F	Covering letter to medical officers in-charged	218
Appendix G	Covering letter to chief pharmacists	219
Appendix H	List of medical and pharmacy schools	220
Appendix I	Students' pilot survey	223
Appendix J	The survey questionnaire for students	228
Appendix K	Covering letters for students' survey	230
Appendix L	Universities curriculum survey	231
Appendix M	Covering letters for university curriculum' survey	234
Appendix N	Prescription contents data collection form	235
Appendix O	Median prices for data collected from 5 private retail pharmacies survey	236

## **ABBREVIATION**

DM type II	Diabetes Mellitus type II
EM	Essential Medicines
EMC	Essential Medicines Concept
EML	Essential Medicines List
FDA	Food and Drug Administration
G	Generic
IB	Innovator Brand
IPP	Intellectual Property Protection
MOH	Ministry of Health
NDP	National Drug Policy
NEML	National Essential Medicines List
NGOs	Nongovernmental Organizations
RM	Malaysian Ringgit
TNC	Transnational company
TRIPS	Trade-Related Aspect of Intellectual Property Rights
WHO	World Health Organization
WTO	World Trade Organization
WIPO	World Intellectual Property Organization



## **PENILAIAN KEKANGAN PENDIDIKAN DAN EKONOMI TERHADAP PELAKSANAAN KONSEP UBAT PERLU DI MALAYSIA**

### **ABSTRAK**

Walaupun senarai Ubat Perlu Kebangsaan (NEML) di Malaysia telah dilancarkan pada tahun 2000, tidak terdapat sebarang kajian yang telah dijalankan untuk mengukur tahap kesedaran terhadap konsep ubat perlu di kalangan pengamal perubatan, ahli farmasi dan pelajar-pelajar perubatan dan farmasi, atau untuk mengukur tahap keupayaan membeli ubat untuk rawatan penyakit kronik. Kajian ini mengandungi tiga bahagian. Bahagian pertama mengenal pasti pengetahuan, tingkah laku dan praktis pengamal perubatan dan ahli farmasi masing-masing di klinik dan hospital kerajaan. Dua soal selidik yang berasingan telah digunakan. Soal selidik telah dipos ke 113 klinik dan 60 hospital di Semenanjung Malaysia. Daripada bilangan tersebut, 186 pengamal perubatan (65 klinik) dan 277 ahli farmasi (44 hospital) telah memberikan respons kepada soal selidik tersebut. Nilai median pengetahuan adalah 5 bagi kedua-dua kumpulan daripada 8 poin; nilai skor median bagi tingkah laku adalah 17 dan 18 daripada 25 poin, manakala nilai skor median bagi praktis adalah 8 dan 6 daripada jumlah total 10 bagi kedua-dua pengamal perubatan dan ahli farmasi, masing-masing. Bahagian kedua telah dijalankan untuk mengukur pengetahuan dan tingkah laku pelajar-pelajar perubatan dan farmasi di universiti-universiti kerajaan di Malaysia terhadap ubat perlu dan untuk menilai kurikulum universiti jika konsep ubat perlu diajar kepada pelajar-pelajar prasiswazah. Soal selidik untuk pelajar dan kurikulum telah dipos ke 5 universiti.

Sejumlah 250 pelajar perubatan dan 314 pelajar farmasi telah melengkapkan soal selidik dengan memberikan kadar respons 60% dan 100% bagi fakulti perubatan dan farmasi setiap satu. Nilai skor median bagi pengetahuan adalah 3 dan 4 daripada 8 poin, manakala skor median bagi tingkah laku adalah 8 bagi kedua-dua kumpulan daripada 10 poin bagi pelajar perubatan dan farmasi setiap satu. Bahagian ketiga telah dilaksanakan untuk menilai tahap keupayaan membeli ubat perlu bagi rawatan penyakit hipertensi, diabetes mellitus jenis II, asma dan kombinasi penyakit-penyakit kronik tersebut. Kajian kes telah dijalankan untuk menilai kandungan preskripsi yang diperolehi daripada borang tuntutan klinik panel USM bagi tahun 2006. Tahap keupayaan membeli ubat yang digunakan telah diukur menggunakan harga ubat daripada kedai farmasi. Tahap keupayaan membeli dinilai sebagai bilangan hari gaji yang diperlukan untuk membiayai rawatan untuk tempoh satu bulan oleh staf USM yang berpendapatan paling rendah. Tahap keupayaan membeli didapati rendah bagi kebanyakan produk-produk berjenama, bagi kebanyakan rawatan kombinasi dan rawatan bagi kes-kes penyakit berganda. Justeru itu, usaha diperlukan di Malaysia untuk memfokus bagi meningkatkan kesedaran di kalangan profesional kesihatan terhadap konsep ubat perlu. Komitmen kerajaan juga diperlukan untuk memenuhi keperluan rakyat yang mengalami penyakit kronik.

## **EVALUATION OF EDUCATION AND ECONOMIC BARRIERS IN IMPLEMENTATING ESSENTIAL MEDICINES CONCEPT IN MALAYSIA**

### **ABSTRACT**

Although the National Essential Medicines List (NEML) in Malaysia was launched in 2000, there were no studies conducted to measure prescribers, pharmacists and medical and pharmacy students' awareness on essential medicines concept, or to measure affordability of actual prescriptions used for treatment of chronic conditions. This study consists of three parts. The first part determined knowledge, attitude and practice of prescribers and pharmacists among government clinics and hospitals, respectively. Two separate survey questionnaires were used. Questionnaires were mailed to 113 clinics and 60 hospitals in west Malaysia. Out of 65 clinics (186 prescribers) and 44 hospitals (277 pharmacists) responded to the survey. Knowledge median scores were 5 for both groups; out of 8 points, attitude median scores were 17 and 18, out of 25 points, while practice median scores were 8 and 6 out of 10 points for prescribers and pharmacists, respectively. The second part was conducted to measure knowledge and attitude of medical and pharmacy students on essential medicines in Malaysian government universities and to check university curricula if essential medicines concept is taught to undergraduate students. The survey questionnaires for students' and the curriculum survey were mailed to 5 universities. A total of 250 medical students and 314 pharmacy students completed questionnaire for a valid response rate of 60% and 100% for medicine and pharmacy schools, respectively. Knowledge median scores were 3 and 4 out of 8 points, while

attitude median scores were 8 of the two groups out of 10 points for medical and pharmacy students, respectively. The third part was conducted to evaluate affordability of essential medicines used in treatment of hypertension, diabetes type II, asthma and multiple chronic conditions of the previous diseases in Malaysia. A case study measured prescriptions contents of USM panel clinics' claim forms for year 2006. Affordability of medicines used was calculated using private retail pharmacies prices. Affordability was expressed as number of days' salary required by a USM lowest wage workers to pay for one month treatment. Low affordability was noted for most brands products, most combined treatments and all multiple chronic cases treatments. Therefore, efforts are required in Malaysia to focus on increasing the awareness of health professionals on essential medicines concept. A commitment by the government is also required to meet the needs of citizens who suffer from chronic diseases.

## CHAPTER 1

### INTRODUCTION

#### 1.1 Background

##### 1.1.1 Definition and general principles of essential medicines

The principal idea of essential medicines list (EML) is that certain medicines have more importance than others in terms of priority for treating some diseases conditions (Chirac, 2003). The essential medicines concept could lead to better access to health care through enhanced medicine management and the use of efficient financial resources. Essential medicines are one of the key primary health care elements (Quick, 2003).

According to the World Health Organization (WHO) “Essential medicines are those that satisfy the priority health care needs of the majority of the population. They are selected with due regard to public health relevance, evidence on efficacy and safety and comparative cost-effectiveness. Essential medicines (EM) are intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality and adequate information, and at a price the individual and the community can afford. The implementation of the concept of essential medicines is intended to be flexible and adaptable to many different situations; exactly which medicines are regarded as essential remains a national responsibility” (WHO, 2004).

Essential medicines list is one of the key features of the national medicine policy and essential medicines program (Ratanawijitrasin *et al.*, 2001). Key components of a national medicine policy contains many plans include; selection of essential medicines, affordability, medicine financing, supply system, medicine regulation, rational use of medicines, research, human resources development and

finally monitoring and evaluation. All components work together for better health care for the population (WHO, 2001a).

WHO first formulated the concept of essential medicines in 1970, with definition of essential medicines (EM) in 1975 and publication of the first WHO model of essential medicines list in 1977 (WHO, 2004). The list contained 208 generic medicines, which was easily adopted by any country based on the local situations and needs. The aim was to improve quality of health and make medicines affordable, available and improve their use (Dunne, 1996). WHO works with all countries to implement medicine policies and EML, and as a result over 150 countries have an essential medicine list, three quarters of which were recently updated (Quick, 2003; WHO, 2004). Reidenberg and Walley (2004), mentioned that many rich countries applied the EML in order to improve health care and manage the cost of medicines, as EML maintains medicine affordability in the selection of EM.

### **1.1.2 Essential medicines concept**

The reasons for implementing the concept of essential medicines are due to the following reason: (WHO, 2001a)

- Essential medicines which are selected on the basis of safe and cost-effective clinical guidelines lead to more rational prescribing, and therefore lead to higher quality of health care and better value for money;
- Training of health workers and medicine information in general can be more focused;
- Prescribers gain more experience with fewer medicines and more easily recognize medicine interactions and adverse reactions;

- Quality assurance, procurement, storage, distribution and dispensing are all easier with a few number of medicines;
- The procurement of fewer items in larger quantities results in more price competition and economies of scale.

All these are even more important in resource-poor situation where the availability of medicines in the public sector is often not on regular basis. Under such circumstances, measures which ensure supply of essential medicines would result in real health gains and in increased confidence in health services (WHO, 2003b).

### **1.1.2 (a) Practical implications of essential medicines concept**

National essential medicines lists and national medicine formularies, together with clinical guidelines should serve as the basis for formal education and in-service training of healthcare professionals. In addition, they should also be used in public education about medicine use and serve as the main basis for public sector medicine procurement, distribution, as well as for medicine donations (Quick *et al.*, 1997).

Health insurance schemes often use a limited list of medicines, the cost of which they will reimburse. This is one of the most common applications of the principles of medicine selection in developed countries (Quick *et al.*, 1997). In developing countries, health insurance is less widespread, but coverage is growing and schemes are generally based on reimbursement for essential medicines. In view of the rapidly rising costs of medicines in most countries, it can be safely stated that all forms of health insurance scheme would ultimately need one process of medicine selection or another. Essential medicines lists and teaching about the benefits of medicine selection could also be used to influence practices in the private sector,

through the basic training of medical students, and programmes of continuing medical education with universities and professional associations (WHO, 2001a).

### **1.1.2 (b) Challenges facing essential medicines concept**

There may be opposition to the use of the essential medicines list. Prescribers may see it as placing some restrictions on their clinical freedom, while pharmacists may be worried about the financial implications. Manufacturers may have fears of their market being eroded, and consumers may think they are being offered second-rate, cheap medicines. If these concerns are not addressed, the concept of selection and the use of an essential medicines list may not be accepted. This is the reason why medicine selection process should be consultative and also justifies why informing and educating those affected is important (Quick *et al.*, 1997).

### **1.1.2 (c) Barriers to implementing essential medicines concept**

According to Tetteh (2007), access to essential medicines reduces disease burden. However, lack of access to EM is still a wide spread problem worldwide (Laing *et al.*, 2003). Many factors affect access to essential medicines and hinder the implementation of the essential medicines list (EML) and essential medicines concept (EMC) in many countries; these factors thus act as barriers to medicines reaching the public. These barriers are:

#### **i. Medicine availability**

Many people throughout the world cannot obtain the medicines they need because the medicines are not available (WHO, 2001a). In a book authored by Zafrullah Chowdhury (1995), developing countries' population which account for



about 75% of the world population consume only about 14% of the medicine supply for the whole world, which indicates low availability. In addition, Chowdhury (1995), further mentioned that irrational medicine use is common due to the promotion of many brands even though in the developing countries the largest numbers of brands are found due to lack of developed regulatory systems and quality control mechanisms. Medicine availability is one of the main barriers preventing essential medicines from reaching the public in the poor countries (Pécoul *et al.*, 1999). Moreover, the major barrier in poor countries is the prevention of availability of the essential new medicines needed for treating diseases such as TB, multidrug resistant malaria, etc (Ruxin *et al.*, 2005).

## **ii. Economic barriers**

Lee *et al.*, (2002), define affordability as free access to good and services without economic barriers. Therefore, high costs of medicines make medicines poorly accessible to the public even for important treatments in rich countries (Lopert *et al.*, 2002), because high costs lead to affordability barrier to medicines (Tetteh, 2007). In the United States there is no regulatory mechanism to medicine prices, therefore one in every four elderly patients limit their medicine use because of high prices (Ellner, 2003). Economic barriers due to costs of treatment and fees for services make health care unaffordable to individuals. Medicine affordability affects all social groups in all countries, but the poor are the most affected (Shalev, 2004).

Transnational companies (TNCs) market their medicines all over the world; some of the medicines may be of doubtful efficacy. However, TNCs have little or no concern regarding the usefulness of these medicines or about the serious adverse reaction they cause as they do about obtaining high profits, thus resulting in high

medicine prices (Chowdhury, 1995). Research and development (R&D) is an additional reason for high cost of medicines, although few therapeutic gains may be recorded especially in third world countries where there is poor medicine regulatory machinery (Chowdhury, 1995; Pécoul *et al.*, 1999). In low income countries combined effects of taxes, duties, distribution costs and retail margins result in a final medicine price that is commonly more than double and sometimes 35 times the producer or importer prices (Quick, 2003). WHO (2001a) is concerned with this phenomena because this result in many people all over the world not being able to obtain the medicines they need because it becomes unaffordable.

The problem of increasing medicine costs is not restricted to developing countries. As most of the cost increases may be due to the introduction of new medicines, medicines selection becomes important even for rich countries. Therefore, the concept of essential medicines is not that of the developing countries alone (Hogerzeil, 2004).

### **iii. Education barriers**

Doctors see medicines as means of stopping illness and are often bothered that pharmaceutical industries' concern is mainly for profits because of:

- the economics of medicine production;
- health care marketing strategies of medicine industries; and
- high medicine costs and affordability.

These are usually not apart of the medical education curriculum in many developed and third world countries. Therefore, this lack of knowledge can make doctors easily convinced by the marketing promotion of pharmaceutical companies about new medicines and by any hints regarding their clinical freedom restriction.

Eventually, the patients are the apparent purchaser of medicine of choice of their medicine as prescribed by the doctors. Therefore, doctors must have knowledge and be aware of the pharmaceutical situation and essential medicines concepts (EMC) which allows them to prescribe medicines as a matter of priority (Chowdhury, 1995).

According to Laing *et al.*, (2001), in most developing countries, regular education of healthcare professionals is minimal, with little incentives for participation in continuous education programmes for promotions rather than to improve the quality of health care. Therefore, the production of printed bulletins and pharmaceutical newsletters can help to increase healthcare professionals' awareness of EMC. In addition, Ruxin *et al.*, (2005), stated that human resources inadequacies such as decline in number of pharmacists and technicians are one of the major barriers for access to essential medicines. On the other hand, Quick (2003) mentioned that presently, at least 88 countries have introduced the essential medicines concept into the curricula of medical and pharmaceutical students. Many people all over the world cannot obtain the medicines they need because there are no trained personnel to prescribe (WHO, 2001a).

Many countries frequently lack adequate supplies of medicines. The reason behind medicine shortages may indicate attitude and behavior of the government, prescribers and dispensers (WHO, 1988). Organized physicians have opposed EMC in many developing countries (Kanji and Hardon, 1992). Educational programs and strategies must be applied for health students, physicians, nurses and pharmacists to improve their attitudes and behaviors towards EMC (WHO, 1988). Knowledge and attitude of healthcare professionals are important factors for implementing specific concepts. Health professionals were prevented access to some medical use of medicines due to their attitudes and knowledge toward that medicine. An effort is

made to educate physicians and nurses about the principle of palliative care (Rajagopal and Joranson, 2007).

Healthcare professionals (prescriber and dispenser) should provide essential medicines (EM) as a matter of priority, to help people to select their medicines between the thousands of promoted medicines. This improves the essential medicines list (EML) implementation by bridging the gap between the theory of essential medicines list document and the actual implementation in the field.

#### **iv. Patent regulations**

Patent is a property right granted by a sovereign state to a product that has not been previously disclosed elsewhere in the world. Patent gives the owner the right to prevent others from making, using, offering for sale or selling the product for a period of 20 years (Lehman, 2003).

Although developments in Intellectual Property law in the wake of WTO's Doha Declaration affirmed the priority of public health over the protection of patents, it agreed that the 50 least developed member countries are not obliged to implement the patent law for pharmaceuticals until January 1, 2016 (Lehman, 2003). The Doha declaration acknowledged the short sightedness of the TRIPS agreement rule mandating that member countries could break patent only in public health endogenously, in order to produce generic medicine for local markets. Therefore, developing countries without local industries producing medicines will limit access to essential medicines (Westerhaus and Castro, 2006), but access to patent generic medicine from other countries remain restricted.

Patent is controlled by World Intellectual Property Organization (WIPO) and World Trade Organization (WTO). In case of WTO patent regulation are contained

in the agreement of Trade-Related Aspect of Intellectual Property Rights (TRIPS). Under the present intellectual property regulation a patent may protect the sale of medicines for as long as 35 years, putting those medicines out of reach of poor people because of high prices (WHO, 2006). Moreover, according to Chowdhury (1995), patents enable pharmaceutical industries to adopt high prices. A third of the world's population's lack of access to quality medicines is due to patent protection of many essential medicines. Stronger protection of patents through introduction of patent protection stronger than required under WTO rules, strong intellectual property protection (IPP) and strengthened global rules under TRIPS make medicines unavailable and not affordable to the public (Bale, 2004). WTO rules on TRIPS encourage pharmaceutical industries to put patents as priority over public health care concerns (McDonald, 2007).

Furthermore, to increase access of patients to essential medicines, the medicines should be made affordable because high prices of medicines put them beyond reach of the public even in rich countries. In addition, patents maintain medicines prices high, which far exceed their cost of innovation (Henry and Lexchin, 2002). This means that TRIPS Agreement standards are a factor that limits access to medicines because it does not allow the availability of affordable medicines, due to reducing generic competition in the pharmaceutical market. Therefore, patent of pharmaceutical products does not only limit access to medicines but also elevates medicines prices (Cohen, 2006). In addition, Quick (2003), noted that appropriate use of TRIPS by any country makes cost of new medicines more affordable by patients.

## **v. Technical barriers**

One of the barriers to access to essential medicines is technical barriers. These barriers include counterfeit medicines (Anonymous, 2002; Pécoul *et al.*, 1999), also, John Bell, President of the Commonwealth Pharmaceutical Association, mentioned other factors contributed as a technical barriers to access essential medicines such as in-effective distribution system, non-existent or corrupt regulatory procedures, absence of rational medicine use strategies and lack of pharmacovigilance (Anonymous, 2002).

## **vi. Political barriers**

According to Ellner (2003), political resistances are mainly from pharmaceutical companies which worry or limit their incentives to innovation. In addition, patients may think that essential medicine list (EML) prevents them from access to new medicines and their unique needs for medicines. Kanji and Hardon, (1992), noted that pharmaceutical industries oppose EMC in many developing countries. Limited or no manufacturing to pharmaceutical products by a country is a barrier to access medicines to the population (Cohen, 2006). Many countries have frequently lacked adequate supplies of medicines. Reason behind medicine shortage may indicate attitude and behavior of consumers and the medicine industries (WHO, 1988).

There is great need for political commitment to make implementation of EMC a reality. Therefore, evaluation of these barriers helps to put all hands on check to understand the strengths as well as weaknesses. However, evaluation of these barriers help in updating EML in an evidence based approach rather than experience based.

The study focused only on education and economic barriers because they are major barriers, and there are problems reported about the two barriers. In addition medicines availability was investigated by two researchers in all different sectors all over the country (Saleh and Ibrahim, 2005; Babar *et al.*, 2007). Also the three other barriers are relatively minor barriers.

### **1.1.3 Promoting the essential medicines concept**

There have been lots of benefits recorded with the use of essential medicines list in the public sector. However, in most low- and middle-income countries, the majority of the people are treated with medicines from the private sector, paid for out-of-pocket. Often, these consumers are prescribed or dispensed as high-priced medicines, often in small quantities, rather than as therapeutic amounts of essential medicines. Promotion of non-essential medicines often results in over-treatment of mild illness, inadequate treatment of serious illnesses and overuse of antibiotics. Widespread prescription and sale of non-essential medicines means that households, especially poor households, are not getting the best health care value for their money and may ultimately not receive the treatment they need (WHO, 2001a).

WHO vision that people all over the world should have access to essential medicines (EM) which they need medicines that are safe, effective, and of good quality and that the medicines are prescribed and used rationally. Access to EM especially for HIV/AIDS, tuberculosis (TB) and malaria are critical to global efforts by WHO to prevent millions of death each year, reduce peoples' suffering and help reduce the diseases treatment cost on the poorest families. WHO estimates that over 10.5 million lives per year could be saved by 2015, also boosting economic growth and social development by expanding access to existing interventions for infectious

diseases, maternal and child health, and no eradicating communicable diseases. Medicines' cost is the second highest expenditure after staff salaries in many developing countries. It is also the second highest household expenditure after food (WHO, 2004). Health is fundamental human rights. Highest access to health care, which include access to EM is a prerequisite for realizing those rights. This means that essential medicines are a human right i.e. a part of the right to health (Hogerzeil *et al.*, 2006).

WHO goal is to help save lives and improve health by ensuring medicines quality, efficacy, safety and rational use of medicines including traditional medicines, and by promoting equitable and sustainable access to EM, particularly for the poor. EM save lives, reduces sufferings and improves health situations, but only if they are of good quality and safe, available at low prices and properly used. WHO (2004) further stated that in many countries today not all these conditions are being met.

Essential medicines (EM) have a huge economic impact on countries and household in developing countries. Due to high prices, medicines account for 25% - 70% of all health care expenditure, compared to less than 15% in most high income countries. For governments and NGOs providing primary health care, medicines are the largest expense after personnel costs. For households in low income countries, medicines represent 50% - 90% of out of pocket spending on health, yet in some countries less than half of people living in poor households receive all the medicines they need for curing illnesses, with one third receiving none of the medicines they need (WHO, 2004).



The reasons behind higher access to essential medicines and those efforts that are needed to close the gap to access is attributable to fundamental economic, social and educational factors that directly affect the health sector (Quick, 2003).

The main projects to improve the use of medicines is to establish procedures for developing and revising an essential medicine list (or hospital formulary) based on treatments of choice, and to encourage targeted, problem-based in-service educational programs by professional societies, universities and the Ministry of Health, and request for regular continuing education for the licensure of healthcare professionals (Laing *et al.*, 2001).

#### **1.1.4 Advantages of essential medicines list**

Essential medicines play a crucial role in many aspects of health care. Limited list of essential medicines lead to easy procurement; efficient storage and distribution due to low stocks, and this may minimize medicines wastages; and assured quality and easy dispensing (WHO, 2003a). In addition, it is also helpful for prescribers in focusing on few medicines, which result in more experience, better recognition of adverse medicine reaction, more rational use as in case of Mexican EML, where the list is used as a good instrument for rationalization of medicine therapy (Kravzov and Altagracia, 1994). Also it focuses education efforts of patients to reduce confusion and increase adherence to treatment (Quick *et al.*, 1997).

Moreover, EML is an aid to the following:

- Procurement, due to the bulk purchase of generic medicines which is often of lower cost than the brand;
- It makes for competition between generic suppliers and leads to lowering of prices;

- Choice of specific medicines helps in possibility of lower medicines waste (Redenberg, 1996); and
- EML also is used in medicine distribution and procurement and for the development of national formulary (NF) (Laing *et al.*, 2001);

Furthermore, EM enables health authorities and policy makers to ensure those medicines are available on all health care system levels; it helps people to choose their treatments between large numbers of promoted medicines; it also helps healthcare professionals to know medicines that must be prescribed and dispensed as a matter of priority (Chirac, 2003). As in the case of Mali where NDP aimed to make medicines more available while improving appropriate uses by rational prescribing (Maïga *et al.*, 2003). The national essential medicine list shows public health priorities which help policy makers to know the country's national priorities for public procurement and reimbursement and for training and educating healthcare professionals (Smith and Tickel, 2003). The most important is EM are those that are aimed at reducing morbidity and mortality in the developing countries (Pécoul *et al.*, 1999).

#### **1.1.5 Selection of essential medicines**

Essential medicines (EM) are one of the main basic principles of a national medicine policy because it helps to set all requirements of the pharmaceutical system (WHO, 1988). Medicine selection, preferably linked to national clinical guidelines is a crucial step in ensuring access to essential medicines and in promoting rational medicine use, because no public sector or health insurance system can afford to supply or reimburse all medicines that are available in the market (Hogerzeil, 2003).

The selection of essential medicines is a two-step process. Market approval of a pharmaceutical product is usually granted on the basis of efficacy, safety and quality and rarely in the comparison with other products already in the market or based on cost. The regulatory decision defines the availability of a medicine in the market. In addition to this, most public medicine procurement and insurance schemes have mechanisms to limit procurement or reimbursement of medicine costs. For these decisions, an evaluation process is necessary, based on a comparison between various medicine products and in considerations of value for money. This second step leads to a list of essential medicines.

#### **1.1.5 (a) Selection criteria**

The treatment recommended and the medicines selected depend on many factors such as; the pattern of diseases prevalence, treatment facilities, the training and experience of available personnel, financial resources and genetics, demographic and environmental factors. The type and number of essential medicines selected depends on the circumstances in which the medicines are to be used, but the selection should be based on the EMC and in particular, on the following criteria which are used by the WHO expert committee on the use of essential medicines, that only medicines for which sound and adequate evidence of efficacy and safety in a variety of settings is available should be selected. Relative cost-effectiveness is a major consideration in the choice of medicines. In comparing between medicines, the total cost of treatment - not only the unit cost of the medicine – must be considered. Also, it should be taken into account the treatment in relation to the savings (i.e. surgery and hospitalization) and be compared with its efficacy; in some cases, the choice may also be influenced by other factors such as pharmaco-kinetic properties or by

local considerations such as the availability of facilities for manufacturing or storage. Different rates of success of treatment are achieved as a result of improved patients' compliance. Reduction of loss or wastage achieved by using more stable products; selection of pharmaceutical products and dosage form which provide the most favorable benefit / risk ratio; each medicine selected must be available in a form in which adequate quality, including bioavailability can be ensured; its stability under the expected condition of storage must be determined (WHO, 2001a; Quick *et al.*, 1997; WHO, 1988).

Most essential medicines should be formulated as single compounds. Fixed-ratio combination products are acceptable only when the dosage of each ingredient meets the requirements of a defined population group, and when the combination has a proven advantage over single compounds administered separately, in terms of therapeutic effect, safety or patient adherence to treatment (WHO, 2001a; Quick *et al.*, 1997; WHO, 1988).

Selection must be by medicines international nonproprietary (generic) name. If necessary, a cross-index of nonproprietary and proprietary names should be supplied to prescribers and dispensers (WHO, 1988). According to Loff (2003), the benefits of the use and selection of the few numbers of medicines is to improve medicine supply, more rational prescribing and medicines affordability by decreasing medicine prices through bulk purchase of generic medicines. The cost-benefit ratio is the major concern in selecting some medicines to be in the essential medicines list. In other words, selection of EM should be based on the list of pathogenic conditions and complaints and the treatment of choice for these conditions as in the standard treatment guidelines. Therefore, EML is the next step after forming standard treatment guidelines by any country. Manufactures should not be involved in the

decision making process of defining an EML to prevent conflicts of interest (Laing *et al.*, 2001).

#### **1.1.5 (b) Committee for selection of essential medicines**

Committee for selection of the essential medicines includes a wide range of geographical and professional backgrounds, including clinical pharmacology, clinical medicine, international public health, guideline development methodology, systematic literature search methods, risk-assessment and cost-effectiveness analysis. Patient advocacy groups and representatives of the health care industry are invited to comment on the applications and draft recommendations, but are not invited to attend decision-making meetings of the Expert Committee (WHO, 2001b).

#### **1.1.6 Updating essential medicines list**

Essential medicines list (EML) update should be done by an expert advisory committee that consists of clinical pharmacologist and physicians. Updating takes into account new information on medicine efficacy, safety, risk-benefit and data about cost-effectiveness. In other words, updating is due to adapting changes in new medicines, new indications, new diseases, discovered adverse effects and development of resistance. The list of essential medicines should have to be updated every two years (Chirac and Laing, 2001; Chirac, 2003)

#### **1.1.7 Essential medicines for special cases**

##### **1.1.7 (a) Essential medicines for children**

Essential medicines for children are those medicines for use by pediatric only. In the past FDA criteria for selection EM for children was that medicine

content used in therapy of neonates has therapeutic value document, data for dosage recommendation, therapeutic indication and toxicity; finally, current labeling for neonatal use must exist, then frequency of use, low therapeutics index, reports of serious toxicity of the medicine (Kauffman, 1999). According to Hogerzeil (2006), WHO is boosting EM for children which aims firstly for the prequalification of pediatric medicines for treating AIDS, TB and Malaria and secondly, ensures suitable pharmaceutical formulation for children for all childhood disease in the EML to help fill up the gap to access EM. For this purpose, UNICEF and WHO hope to make access to EM for children because many pharmaceutical industries do not want a progress to EM for children, so that there are no pediatrics formulation withdrawal of many pharmaceutical preparations for children from markets and no registration of these products in many countries. Moreover, many medicines are not in suitable formulations and there is no funding for children (Anonymous, 2006).

#### **1.1.7 (b) Essential medicines for rare diseases**

Orphan medicines are medicines for rare diseases or low prevalence disorder. Some developed countries developed this policy for individual patients with rare disorders, although WHO has not boosted the rare essential medicines yet, but it is in use in the United State of America and European Union (Stolk *et al.*, 2006). Reidenberg (2006) noted that the orphan medicine is not an absolute essential medicine unless identified as “essential”.

#### **1.1.8 Implementation of Malaysian essential medicines list**

The initial idea for implementing national essential medicines list (NEML) in Malaysia was in 1996. The idea came from the fact that, there must be some

measures to obtain health care cost of medicines especially in the private health sectors in order to maintain this sector at an affordable level. Also one of the aims of implementing NEML was to maintain medicines prices (MOH, 2006a).

The Malaysian national essential medicines list was launched on January 27, 2000; the list was developed in four years. Table 1.1 shows a chronology of major events before implementing the national essential medicine list.

**Table 1.1: Chronology of major events before implementing the national essential medicine list in Malaysia**

Date	Event
January 31 <sup>st</sup> , 2000	Editorial Voice : Status Quo in medicine use
January 30 <sup>th</sup> , 2000	Essential medicines and telehealth
January 27 <sup>th</sup> , 2000	Launching Ceremony – National Medicine List
December 5 <sup>th</sup> , 1999	Profit takes priority over care
August, 1999	Excerpt of MMA-PhAMA Dialogue Report on NEML
March 22 <sup>nd</sup> , 1999	National Essential Medicine List Seminar in Kuala Lumpur
February 11 <sup>st</sup> , 1999	6 <sup>th</sup> Meeting of National Essential Medicine List in Kuala Lumpur
July 4 <sup>th</sup> , 1998	Internal Circulation of Draft National Essential Medicine List
July 2 <sup>nd</sup> , 1998	5 <sup>th</sup> Meeting of National Essential Medicine List in Kuala Lumpur
June 25 <sup>th</sup> , 1998	Going Generic and Bringing Health to All
September 5 <sup>th</sup> , 1997	Seminar on Essential Medicines Concept – An International Perspective
June 23 <sup>rd</sup> , 1997	4 <sup>th</sup> Meeting of National Essential Medicine List in Kuala Lumpur
October 25 <sup>th</sup> , 1996	3 <sup>th</sup> Meeting of National Essential Medicine List in Kuala Lumpur
September 3 <sup>rd</sup> , 1996	2 <sup>th</sup> Meeting of National Essential Medicine List in Kuala Lumpur
April 22 <sup>nd</sup> , 1996	Malaysian Pharmaceutical Society rejected a proposal supporting National Essential Medicines Lists at its 29 <sup>th</sup> AGM held in Kuala Lumpur

**“Table 1.1 Continued”**

<b>Date</b>	<b>Event</b>
March 21 <sup>st</sup> , 1996	Inaugural meeting on National Essential Medicines List in Kuala Lumpur
March 2 <sup>nd</sup> , 1996	National Essential medicines List hailed
February 17 <sup>th</sup> , 1996	Announcement by the Health Minister in the local press
February 16 <sup>th</sup> , 1996	Press Release : Medicine Prices in Malaysia (Excerpt of Proposal)

Source: USM Poison Centre Archive

The list was developed by the Ministry of Health together with the Malaysian Pharmaceutical Society, the Federation of Private Medical Practitioners, the Malaysian Medical Association, the Pharmaceutical Association of Malaysia, The Malaysian Organization of Pharmaceutical Industries, Universiti Kebangsaan and Universiti Sains Malaysia (Ritikos, 2000).

The NEML was formulated using the Ministry of Health’s (MOH) Medicines List as a basis. The MOH Medicines List which was introduced in 1983 serves as the essential medicines list for the public healthcare sector. Every medicine in the list was classified according to the category of medical officer or healthcare provider allowed to prescribe it. The list is dynamic and is reviewed every 4 months by a panel consisting of specialists from the main disciplines and pharmacists (MOH, 2006a).

The committee for creating the National Essential Medicines List decided that the List shall consist of two parts. The first part called the Essential Medicines List contains all preparations needed for primary and secondary healthcare treatment commonly used by medical officers and paramedics in primary healthcare facilities. Several preparations used in tertiary care are included in order to be consistent with



WHO's model of Essential Medicines List. This part contains 358 chemical entities and 605 preparations (MOH, 2006a).

The second part called the supplementary List consists of medicines used by specialists for tertiary level treatment. This part contains 257 chemical entities and 391 preparations. While government's hospitals have used a list of 680 generic medicines since 1983, this is the first time such a list has been extended for private sector use. The Malaysian Health Minister Datuk Chua Jui Meng said "the formation of the list expects to bring down the cost of medicines as well as the healthcare, because the prescription of generic medicines brought down the cost by 50 to 70 per cent as mentioned in WHO report" (Azhar, 2000).

Committee for selection of NEML included representatives from various sectors such as relevant government agencies, professional bodies, universities and the pharmaceutical industry. Sub committees were set up to help in various aspects of the list (MOH, 2006a):

- medicines list contents
- medicines prices
- medicine information
- logistics

Prices for all the medicines are provided in a separate book (Abdul Razak, 2000).

## **1.2 Problem statement**

### **1.2.1 Health professional awareness on essential medicines in the Western Pacific Region**

WHO reported that in the Western Pacific Region, health workers have misconceptions about the essential medicines concept. They think that essential medicines have low efficacy and quality, cheap and may not satisfy patients' need. Moreover, healthcare professionals think that their clinical freedom may be restricted by adhering to the list of essential medicines (WHO, 2005). This misconception may be due to the fact that there is no education for professionals as well as students for the medicine policy and the concept of essential medicines; or could be due to their negative attitude toward essential medicines. Low awareness and acceptance of essential medicines concept can act as a barrier to implementing this concept in the country.

### **1.2.2 Medicines affordability in Malaysia**

It is a fact that in Malaysia, there is no regulatory system for medicines prices. This justifies why many essential medicines used in treatments of many chronic diseases are not affordable. Furthermore, Malaysia depends on imports of medicines, although the essential medicines list enables the country to focus on becoming self-reliant where the generic equivalence of essential medicines can be manufactured and popularized to meet health needs for the majority of the people (Ibrahim and Bahri, 2003). According to Azhar (2006) in Malaysia imported medicines prices have rise by up to 28 per cent annually in the last 10 years, especially daily used medicines. In addition, Chowdhury (1995), reported that most medicines prices range from 10-293% higher than in Australia and the UK. In

addition, prices are not stable, which increases annually by 20.7% when the rate of inflation was 7%.

A survey on these prices was done by (Babar *et al.*, 2007), which showed median prices ratios for some medicines for innovator brand (IB), the most sold generic (MSG), and the lowest priced generic (LPG) for government procurement prices, private retail pharmacy, and dispensing doctor sector as shown below (Table 1.2).

**Table 1.2: Medicines prices in different sectors comparing with international reference price**

Sectors	IB	MSG	LPG
Government purchase price	2.4 X	1.56 X	1.09 X
Private retail pharmacies	16 X	6.89 X	6.57 X
Dispensing doctor	15 X	7.5 X	7.5 X

X=Times the international reference price

In addition, the study finding shows that most medicines in private sector have higher prices than the public sector and international reference prices; those medicines include off-patent one's.

High medicine prices justify why some medicines of chronic diseases are not affordable. Chronic diseases need treatment for a life time. Therefore, if patient cannot afford medicines, this could lead to more serious illnesses and complications.

### **1.3 Rationale of the study**

In Malaysia national EML was launched in January 2000, and there is no study has been conducted to look into this issues recorded to the implementation of the EMC. This study, as the first of its kind in Malaysia, it considered as an important contribution, especially because it provides baseline evidence to monitor changes regarding transitions toward essential medicines concept' awareness among practitioner as well as future healthcare professionals. In addition, problems of medicines affordability are still reported after the launched of EMC, although the two studies were using hypothetical methodology regarding treatments.

In the absence of data regarding to what extent practitioners and future health professionals know about the essential medicines concept, a survey based study is the most suitable methodological approach in our setting. Health workers included are prescribers, pharmacists, and the future health professionals such as medical students and pharmacy students, to ensure that students know about the concept of essential medicines before graduation, because there might be no time for them to know or to consider issues such as the concept of essential medicines after graduation.

Awareness of practitioners and future health workers on the essential medicines concept is important because they help consumers to select their medicines between the thousands of promoted medicines and improve the implementation of the essential medicines concept by filling the gap between the theory of essential medicines and the actual implementation of the list. Their misconceptions act as a barrier to implement the concept of essential medicines.

Although medicines are free of charge in the public sectors, but when it is not available, or prescription does not include all medicines for a month's therapy to treat chronic diseases, patient would have to buy their medications from the private